VivoSeq
Neurology

Neurotoxicity

39

Pipeline Programs↗

9

Active Trials↗

22

Companies Involved↗

Neurotoxicity is a moderately active landscape with 39 programs across 22 companies. The most active players are Alnylam Pharmaceuticals, Jazz Pharmaceuticals, Gilead. 5 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

11/100

Mech. Concentration

6/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

2 programs

Phase 2Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

46 of 49 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody12%Peptide12%Cell therapy12%

Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 100% of 51 pipeline programs.

Analysis

Trial Status

37

clinical trials

Completed15 · 41%
Unknown status8 · 22%
Active, not recruiting4 · 11%
Terminated4 · 11%
Recruiting3 · 8%
Not yet recruiting2 · 5%
Other1 · 3%

Clinical Trials

Trial Activity

37 trials

ADC-induced Neurotoxicity Treated With Duloxetine
Recruiting·FFudan University·Phase 2·NCT06551051·37 enrolled
Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL
Recruiting·CCentre Georges Francois Leclerc·Phase 2·NCT05695313·60 enrolled
Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence of Immune Effector Cell-Associated Neurotoxicity Syndrome
Recruiting·—·Phase 4·NCT06706102·60 enrolled
Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration
Active, not recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT04584983·134 enrolled
Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity
Active, not recruiting·UUniversity of California, San Diego·Phase 2·NCT04800159·40 enrolled
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT04975555·30 enrolled
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT04514029·37 enrolled
Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity
Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 4·NCT07344974·78 enrolled
Stibium Metallicum Praeparatum 6x Versus Placebo in the Prevention of Paclitaxel-induced Peripheral Neurotoxicity
Not yet recruiting·UUniversity of Bern·Phase 3·NCT04715542·120 enrolled
Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients
Completed·—·Phase 2/3·NCT03593304·40 enrolled
Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire
Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00517621·100 enrolled
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Completed·Sanofi logoSanofi·Phase 3·NCT00305188·879 enrolled
a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY
Completed·GGroupe Hospitalier Pitie-Salpetriere·N/A·NCT04290611·500,000 enrolled
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
Completed·Sanofi logoSanofi·Phase 3·NCT00272051·620 enrolled
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Completed·MMarcela V. Maus, M.D.,Ph.D.·Phase 2·NCT04150913·15 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)